Companies › Advenchen Laboratories
2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 3; Oncology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Catequentinib (AL3818) Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor 3 inhibitor; Stem cell growth factor receptor inhibitor | KDR, FLT4, KIT, PDGFRB | Phase 3 | Alveolar Soft Part Sarcoma | Dec 2027 |
| AL8326 | – | Phase 1 | Non-small Cell Lung Cancer; Solid Tumor | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03016819 | Catequentinib (AL3818) | Phase 3 | Alveolar Soft Part Sarcoma | Oncology | Dec 2027 |
| NCT06794957 | AL8326 | Phase 1 | Non-small Cell Lung Cancer | Oncology | Dec 2027 |
| NCT07392736 | AL8326 | Phase 1 | Solid Tumor | Oncology | Nov 2029 |
OSE Immunotherapeutics Advenchen Laboratories Nanjing Clarity Pharmaceuticals TYK Medicines Impact Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.